European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim

View source ↗

Summary

The EMA recommends suspension of the diabetes medicines rosiglitazone-containing products Avandia, Avandamet, and Avaglim due to cardiovascular safety concerns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Avaglim (rosiglitazone)
• Avandamet (rosiglitazone/metformin)
• Avandia (rosiglitazone)